Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis

Thorban, Stefan; Rosenberg, Robert D.; Busch, Raymonde; Röder, R.

doi:10.1054/bjoc.2000.1199

Cited by 47 publications

(36 citation statements)

References 26 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The authors concluded that an autocrine CXCL12 secretion from tumor cells might activate CXCR4 on the tumor cells, resulting in distant metastases. The interaction of gastric cancer-expressed CXCR4 and SDF-1α may be a key event in directing malignant cells to homing organs, which is underlined by findings in esophageal cancer, where the presence of micrometastatic tumor cells in lymph nodes and bone marrow was associated with poorer survival (22,23). As demonstrated in pancreatic cancer, CXCL12 is secreted by cancerous lesions and flows via lymphatic or venous routes to its metastatic sites (24).…”

Section: Discussionmentioning

confidence: 99%

SNP rs1801157 significantly correlates with distant metastasis in CXCL12 expressing esophagogastric cancer

Schimanski

Jordan²,

Schlaegel³

et al. 2011

Int J Oncol

View full text Add to dashboard Cite

Abstract. We performed this study in order to evaluate the impact of the chemokine CXCL12 and its single-nucleotide polymorphism (SNP) rs1801157 on clinicopathological parameters and survival in patients undergoing surgery for esophagogastric cancer. The expression pattern of CXCL12 and its polymorphisms were analyzed by RT-PCR and PCR-RFLP in 69 consecutive fresh-frozen samples of human esophagogastric junction and gastric adenocarcinomas and statistically analyzed. Expression of the CXCL12 (SNP rs1801157) polymorphisms GA/AA significantly correlated with distant metastasis (P=0.026), but not with prognosis. However, CXCL12 expression was not significantly associated with the tumor infiltration depth, lymphatic metastasis and grading. As CXCL12 polymorphisms mediate tumor cell dissemination in esophagogastric cancer, they could represent a marker indicating advanced disease. Antagonists targeting the CXCL12/ CXCR4 axis may be a novel therapeutic option in this entity.

show abstract

Section: Discussionmentioning

confidence: 99%

SNP rs1801157 significantly correlates with distant metastasis in CXCL12 expressing esophagogastric cancer

Schimanski

Jordan²,

Schlaegel³

et al. 2011

Int J Oncol

View full text Add to dashboard Cite

show abstract

“…At diagnosis, 80% of cases are inoperable (2) and, of those with early local disease who have surgery as part of their treatment, only 15% to 30% will be cured (3 -5).…”

mentioning

confidence: 99%

A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response

Ferry

Anderson

Beddard

et al. 2007

Clinical Cancer Research

114

View full text Add to dashboard Cite

Purpose: At presentation, most cases of adenocarcinoma of the esophagus (ACE) are inoperable. Although chemotherapy can prolong survival, patients eventually die as a result of refractory disease. Epidermal growth factor receptor (EGFR) is almost universally expressed in ACE and is a negative prognostic factor. Experimental Design: This open-label, two-center, noncomparative, two-part phase II trial assessed the EGFR tyrosine kinase inhibitor gefitinib (500 mg/d) in patients with advanced, inoperable ACE. The primary end point was tumor response. The effect of EGFR inhibition was also evaluated by gene expression analysis of tumor biopsies taken before gefitinib treatment and 28 days after. Results: Twenty-seven patients were recruited and evaluable for tumor response and safety. Three patients had a partial response and seven had stable disease, giving a disease control rate (partial response + stable disease) of 37%. Drug-related adverse events were generally mild: diarrhea in 19 (grade 3 in three) and rash in 19 (grade 3 in five) patients, and there were no grade 4 drug-related adverse events. Microarray experiments on tumor biopsies showed that gefitinib also down-regulated oncogenes associated with tumor progression. Ki67 (a marker of tumor growth) expression decreased in five of seven biopsies taken before and after treatment. Conclusion: Gefitinib (500 mg/d) is an active and generally well-tolerated treatment for ACE. Studies on endoscopic biopsies are feasible and indicate that gefitinib inhibits both gene expression and cellular biology at 500 mg/d, and these may provide surrogate end points for predictive biomarkers. Further trials of gefitinib are warranted, particularly as patient response seems to be durable and current second-line chemotherapy options have no proven ability to prolong life.

show abstract

“…As taxas de detecção de micrometástase variam de 15 a 38,7%, na medula óssea da crista ilíaca. Thorban et al 28 , em análise multivariada, mostrou importância prognóstica significativa na detecção de micrometástase de medula óssea em pacientes com carcinoma espinocelular de esôfago. Foi evidenciado mau prognóstico de pacientes citoqueratina-positiva em comparação a citoqueratina-negativos com diminuição significativa no tempo de sobrevida geral.…”

Section: Micrometástasesunclassified

Novas perspectivas no estadiamento e tratamento do câncer de esôfago

Fonseca

Furlan

Ferranti

et al. 2007

ABCD, arq. bras. cir. dig.

View full text Add to dashboard Cite

InTRODUÇÃOO câncer de esôfago apresenta-se como uma das neoplasias mais freqüentes e letais. Nas últimas décadas sua incidência vem aumentando consideravelmente com altas taxas de mortalidade em vários países. A doença predomina em faixas etárias avançadas, com maior ocorrência entre a sexta e sétima década de vida, e no sexo masculino, com razão de 4:1 em relação ao minino .Sua incidência varia geograficamente. É alta sobretudo em países como a China, Japão, Turquia, Cingapura A taxa de sobrevida geral após cinco anos é de aproximadamente 10% nas populações ocidentais, em contraste com a de 4% observada na década de 1970 . Apesar desta melhora na sobrevida, seu prognóstico continua insatisfatório e seu tratamento merece novos estudos na busca de melhores resultados.A classificação TNM é utilizada para determinar o grau de disseminação da doença e auxiliar na estimativa do prognóstico, levando em consideração principalmente o número de linfonodos acometidos. Kunisaki et al. 15 , através de 113 esofagectomias, compararam 5 métodos de estadiamento diferentes, observando que os que consideravam o número de linfonodos acometidos ao invés dos padrões de distribuição anatômica das metástases linfonodais, obtiveram melhor relação entre estadiamento e prognóstico. A presença de metástases linfonodais é vista, em muitos estudos, como um fator prognóstico independente. Estes estudos ressaltam a grande importância da realização de estadiamento linfonodal o mais acurado possível.Os métodos atualmente utilizados para ele no pré-operatório são o ultrassom endoscópico, tomografia computadorizada helicoidal e a tomografia com emissão de pósitrons. Ainda assim, estes métodos apresentam baixa

show abstract

Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis

Cited by 47 publications

References 26 publications

SNP rs1801157 significantly correlates with distant metastasis in CXCL12 expressing esophagogastric cancer

SNP rs1801157 significantly correlates with distant metastasis in CXCL12 expressing esophagogastric cancer

A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response

Novas perspectivas no estadiamento e tratamento do câncer de esôfago

Contact Info

Product

Resources

About